A 24-Week, Phase IIa, Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)

By sjmartinez • February 15, 2023

Khanna D, Denton CP, Furst DE, Mayes MD, Matucci-Cerinic M, Smith V, de Vries D, Ford P, Bauer Y, Randall MJ, Ebrahimpoor M, Kupcsik L, Stiers PJ, Deberdt L, Prasad N, Lim S, Pujuguet P, Ahmed S. A 24-Week, Phase IIa, Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA). Arthritis Rheumatol. 2023 Feb 14. doi: 10.1002/art.42477. Epub ahead of print. PMID: 36787101.

Tags: Publications, Rheumatology

Supporting Educational Excellence in Diversity (SEED): faculty development and allyship

Chadha P, Kang EH, Ngo V, Jorrin R, Kochai K, Ackerman-Barger K, Ton H. Supporting Educational Excellence in Diversity (SEED): faculty development and allyship. BMC[...]

Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase in the United States

Pak K, Sachar R, Saab S. Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase[...]

General movement assessments in neonates born with congenital gastrointestinal anomalies: a single site, retrospective study

Soumekh L, Bell S, Espinosa SL, Grogan T, Kesavan K, Calkins KL. General movement assessments in neonates born with congenital gastrointestinal anomalies: a single site,[...]